The file's text, extracted by GovTribe without its formatting.
BPA
| UF BPA NDC Price List for the May 2024 DoD P&T Meeting | | | |
| DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | April 12, 2024 |
| Formulary Notes | | | |
| Class Note(s): Step may apply. | | | |
Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 20144TGTNNFAS1M | Non-Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 20144TGTNNFAS1M | Non-Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
| | Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #3 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 20144TGTNNFAS1M | Non-Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 20144TGTNNFAS1M | Non-Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
| | Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #5 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 20144TGTNNFAS1M | Non-Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 20144TGTNNFAS1M | Non-Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 20144TGTNNFAS1M | Non-Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 20144TGTNNFAS1M | Non-Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
| | Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #9 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 20144TGTNNFAS1M | Non-Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
| | Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #10 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1UFAS1M | Uniform Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 20144TGTNNFAS1M | Non-Formulary | | | | |
| After Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
ADP (non-FAMP Discount)
| UF ADP Appendix for the May 2024 DoD P&T Meeting | | | |
| DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | April 12, 2024 |
| Formulary Notes | | | |
| Class Note(s): Step may apply. | | | |
Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | Scenario 1: One agent may be placed before the step. | | | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | Scenario 1: One agent may be placed before the step. | | | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | Scenario 1: One agent may be placed before the step. | | | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | Scenario 1: One agent may be placed before the step. | | | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | Scenario 1: One agent may be placed before the step. | | | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | Scenario 1: One agent may be placed before the step. | | | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | Scenario 1: One agent may be placed before the step. | | | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | Scenario 1: One agent may be placed before the step. | | | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | Scenario 1: One agent may be placed before the step. | | | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | Scenario 1: One agent may be placed before the step. | | | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | | | |
| After Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
ADP (WAC Discount)
| UF ADP Appendix for the May 2024 DoD P&T Meeting | | | |
| DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | Quotes due: | April 12, 2024 |
| Formulary Notes | | | |
| Class Note(s): Step may apply. | | | |
Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | TUMOR NECROSIS FACTOR INHIBITORS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | Scenario 1: One agent may be placed before the step. | | | | | | |
| | Scenario 1 | 20144TGXX1T2AS1M | Tier 2 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | 20144TGTNT3AS1M | Tier 3 | | | | |
| After Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |